The Alzinova Story

Alzinova AB is a clinical-stage biopharma company dedicated to developing both active and passive immunotherapies to treat Alzheimer’s disease.

The beginnings

The company was founded by scientists at the University of Gothenburg, Sweden, in 2011 after the invention of a unique technology platform, AβCC. The AβCC technology specifically stabilises disease-driving oligomers of the peptide amyloid-β (Aβ), thus enabling the development of disease-modifying therapeutics.

Business angels and the holding company at the University of Gothenburg, GU Holding AB (now GU Ventures AB), provided seed capital and business development support during the early years.

Johanna Hultgren, Björn Larsson, and Per Wester at the bell ringing ceremony during the first day of trading on Nasdaq First North.

Going public

In November 2015, Alzinova completed an IPO and was listed as a publicly traded company on Spotlight (previously ”AktieTorget”) in Sweden. In December 2018 a second round of share issuance was completed.

The new funding enabled the company to effectively move closer to clinical phase, preparing for the first clinical phase 1b study on it’s lead product, ALZ-101 – an active immunotherapy for the treatment of Alzheimer’s disease. ALZ-101  is in clinical development with a phase 1b study in Alzheimer’s patients.

Since March 2019, after completing a third capitalisation round, Alzinova is traded as a public company on the unregulated exchange list NASDAQ First North in Stockholm, Sweden (ticker: ALZ).

Learn more

Learn more about Alzheimer’s disease, our programs and the potential of our unique proprietary AβCC technology.